Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Epilepsy drug could aid stroke victims

12.02.2015

Retigabine preserves brain tissue in mouse models of stroke

Retigabine, a drug approved to treat epilepsy, protected the brain against the effects of ischemic stroke in a study conducted at The University of Texas Health Science Center at San Antonio. Findings are in The Journal of Neuroscience.


New research from The University of Texas Health Science Center at San Antonio suggests that an already-approved drug could reduce the debilitating impact of strokes. MIce that had treatment with a drug called retigabine after a stroke were able to traverse a balance beam without difficulty. Untreated mice displayed a pronounced loss of coordination.

Credit

Drs. Mark S. Shapiro, Sonya Bierbower and James D. Lechleiter/The University of Texas Health Science Center at San Antonio

Sonya Bierbower, Ph.D., and Mark S. Shapiro, Ph.D., of the School of Medicine at the UT Health Science Center, compared treated and untreated mice after a stroke. In a balance beam exercise, untreated mice exhibited a pronounced loss of coordination with slips and falls. Retigabine-treated mice had no difficulty with balance, ambulation or turning around on the beam. See the video.

"You couldn't even tell they had a stroke," Dr. Shapiro, professor of physiology and senior author, said. "They ran across the balance beam like gymnasts."

Effects in tissue

Brain tissue of the treated mice showed significantly reduced damage, compared to untreated mice. Protective effects of the medication were observed up to five days after the stroke, said Dr. Bierbower, lead author and postdoctoral fellow in the Shapiro laboratory.

In an ischemic stroke, blood flow to the brain is suddenly cut off because a vessel gets blocked. The lone treatment approved by the U.S. Food and Drug Administration (FDA) is a clot-busting drug called tPA (tissue plasminogen activator). Since tPA severely thins blood, it can't be administered to many stroke patients.

Different system

The initial injury, the stroke, is followed by a cascade of nerve cell death in the brain. Retigabine works on a different system than tPA, acting directly on the nerve cells to minimize damage.

Retigabine and similar agents open specific proteins called potassium ion channels, whose action stops the electrical activity of nerve cells in the brain. "We thought if we could stop the neurons from firing, thus stopping their electrical activity, we could conserve their resources until their blood supply was restored," Dr. Shapiro said. "This proved to be the case."

Off-label use

Because retigabine is FDA approved under the American brand name Ezogabine as an anticonvulsant, physicians may use it off label in stroke patients. FDA approval for specifically this drug as stroke therapy will require a clinical trial to be conducted, and a team of neurologists and neurosurgeons at the Health Science Center is considering it, Dr. Shapiro said.

"As a leading cause of death and disability, stroke poses a major risk to our society," said David F. Jimenez, M.D., FACS, professor and chairman of the Department of Neurosurgery at the Health Science Center. "It is very exciting to see that our collaborative work with our colleagues in physiology could provide a superb way to ameliorate the harmful effects of stroke on our patients."

Drs. Bierbower and Shapiro both received funding from the National Institute of Neurological Disorders and Stroke to conduct this study. A grant from the American Heart Association has been applied for to further this work. James D. Lechleiter, Ph.D., professor of cellular and structural biology in the School of Medicine, is a co-author of the study.

For current news from the UT Health Science Center San Antonio, please visit our news release website, like us on Facebook or follow us on Twitter.

The University of Texas Health Science Center at San Antonio, one of the country's leading health sciences universities, ranks in the top 13 percent of academic institutions receiving National Institutes of Health (NIH) funding. The university's schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced more than 31,000 graduates. The $787.7 million operating budget supports eight campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways "We make lives better®," visit http://www.uthscsa.edu.

Media Contact

Will Sansom
sansom@uthscsa.edu
210-567-2579

 @uthscsa

http://www.uthscsa.edu/hscnews

Will Sansom | EurekAlert!

More articles from Health and Medicine:

nachricht A better way to measure the stiffness of cancer cells
01.03.2017 | Duke University

nachricht Humans have three times more brown body fat
01.03.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

A better way to measure the stiffness of cancer cells

01.03.2017 | Health and Medicine

Exploring the mysteries of supercooled water

01.03.2017 | Physics and Astronomy

Research team of the HAW Hamburg reanimated ancestral microbe from the depth of the earth

01.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>